Spero Therapeutics (NASDAQ:SPRO) focuses on developing treatments for multi-drug resistant bacterial infections. With a robust pipeline primarily targeting the most critical and hard-to-treat bacterial infections, Spero is committed to innovating within the field of antibiotic development. The company's projects span across various stages of clinical development, aiming to address the growing global threat of antimicrobial resistance. One of their key objectives includes advancing their lead candidates through clinical trials to bring novel therapies to patients in need, while also exploring potential in antibacterial and diagnostic products to broaden their impact on public health. Spero Therapeutics is driven by a mission to save lives by revitalizing the arsenal against bacterial infections.